COMPARATIVE EFFICACIES OF AMPHOTERICIN-B, TRIAZOLES, AND COMBINATION OF BOTH AS EXPERIMENTAL-THERAPY FOR MURINE TRICHOSPORONOSIS

We assessed the activities of amphotericin B deoxycholate, liposomal a mphotericin B, fluconazole, and SCH 39304 against 10 strains of Tricho sporon beigelii in mice dth hematogenous infections. Cyclophosphamide- immunosuppressed CF1 male mice were challenged intravenously with a le thal inoculum of T. beigelii (5 x 10(6) conidia per mouse) and were as signed to different treatment groups or were left untreated. Amphoteri cin B deoxycholate (1 mg/kg of body weight and liposomal amphotericin B (1, 5, and 10 mg/kg) were given parenterally once daily. Escalating doses (5, 10, and 20 mg/kg/day) of fluconazole and SCH 39304 were test ed. We also compared the activity of amphotericin B deoxycholate plus fluconazole (1 and 10 mg/kg/day, respectively) with that of each agent alone. Fluconazole significantly prolonged the survival of mice infec ted with each of the 10 strains tested. Amphotericin B deoxycholate ac hieved various responses, improving the outcomes in mice infected with seven of the strains. Liposomal amphotericin Il was not more effectiv e than amphotericin B deoxycholate against the two strains tested. Bot h fluconazole and SCH 39304 reduced the kidney fungal counts in a dose -dependent pattern, with SCH 39304 being more active than fluconazole against one of the two strains tested. The activity of the combination of amphotericin B deoxycholate plus fluconazole appeared to be superi or to that of either agent alone, especially in reducing the kidney fu ngal burden. Fluconazole is more active than amphotericin B deoxychola te against experimental murine trichosporonosis.